Physician profile
Otis Green
NPI 1629561451
$5,174.10
in general payments reported to CMS, 2019-2025
32 companies · $3,206 in 2025
The $3,206 reported for 2025 was more than what 98% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $36.18 · 2023: $553 · 2024: $1,379 · 2025: $3,206.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,048 · Education: $89.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,047.93 |
| Education | $89.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $998.86 | 2023-2025 | Airsupra, Fasenra, Tezspire |
| Harmony Biosciences LLC | $576.00 | 2023-2025 | Wakix |
| Glaxosmithkline, LLC. | $445.15 | 2023-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Regeneron Healthcare Solutions, INC. | $325.11 | 2023-2025 | Dupixent |
| Boehringer Ingelheim Pharmaceuticals, INC. | $291.07 | 2023-2025 | Jascayd, Ofev, Stiolto Respimat |
| Verona Pharma, INC. | $280.61 | 2025 | Ohtuvayre |
| Avadel Cns Pharmaceuticals, LLC | $225.26 | 2023-2025 | Lumryz |
| Viatris Specialty LLC | $204.03 | 2025 | Yupelri |
| Insmed, INC. | $173.07 | 2024-2025 | Arikayce, Brinsupri |
| Genzyme Corporation | $154.86 | 2023-2025 | |
| Grifols USA, LLC | $152.80 | 2023-2025 | Prolastin-C Liquid |
| Merck Sharp & Dohme LLC | $146.74 | 2025 | Winrevair, Zerbaxa |
| Mallinckrodt Hospital Products INC. | $142.78 | 2025 | Acthar |
| Amgen INC. | $129.66 | 2024-2025 | Tezspire |
| Neurocrine Biosciences, INC. | $119.07 | 2023 | Ingrezza |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Electromed, INC. | $108.22 | 2024-2025 | Smartvest |
| United Therapeutics Corporation | $107.32 | 2025 | Remodulin, Orenitram, Tyvaso |
| Axsome Therapeutics, INC. | $98.20 | 2024-2025 | Sunosi |
| Takeda Pharmaceuticals U.S.A., INC. | $69.61 | 2025 | Glassia |
| Ani Pharmaceuticals, INC. | $68.34 | 2025 | Purified Cortrophin Gel |
| Actelion Pharmaceuticals US, INC. | $57.14 | 2025 | Opsumit, Uptravi, Opsynvi |
| Mylan Specialty L.P. | $44.24 | 2023 | Yupelri |
| Scpharmaceuticals INC. | $38.21 | 2025 | |
| Abbvie INC. | $36.18 | 2021 | |
| Shionogi INC | $30.64 | 2025 | Fetroja |
| Liquidia Technologies, INC. | $28.52 | 2025 | Yutrepia |
| Jazz Pharmaceuticals INC. | $28.07 | 2025 | |
| Zoll Respicardia, INC. | $25.39 | 2024 | Remede System |
| Pfizer INC. | $21.33 | 2025 | |
| Watermark Medical, INC. | $16.29 | 2024 | |
| Alk-Abello, INC | $16.19 | 2025 | Neffy, Ragwitek, Grastek |
| Philips North America LLC | $15.14 | 2025 | Vest Therapy Und |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Otis Green listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.